RISK FACTORS DESCRIBED IN THE REGISTRATION
STATEMENT ON FORM S-4 FILED BY HW GLOBAL, INC. (HOLDCO)
Risks Relating to the Transactions
The number of shares of Holdco common stock that Valtech and Mitraltech shareholders will receive as a result of the Transactions is
fixed, subject to certain adjustments. The value of the shares of Holdco common stock that Valtech shareholders receive is different than at the date the Business Combination Agreement was signed and could be different than at the time Valtech
shareholders vote to approve the ISR Merger.
Upon the effective time of the ISR Merger, the Recipient Parties will receive, as set
forth in a Valtech notice delivered to its shareholders prior to Closing regarding its special meeting, a pro rata portion of: (a) 4,400,000 shares of Holdco common stock to be issued at closing, less escrowed shares of Holdco common stock and less
adjustments, including with respect to certain Valtech indebtedness and transaction expenses; (b) an additional 800,000 shares of Holdco common stock to be issued at closing, less escrowed shares of Holdco common stock, because Valtech successfully
obtained CE Mark approval for Valtechs Cardioband
product; (c) the right to receive escrowed shares of Holdco common stock, if any are ultimately distributed; (d) the right to receive 700,000 shares of Holdco common stock contingent upon a
first-in-man implant of Valtechs Cardioband Tricuspid Product or Valtechs Cardiovalve Product; (e) warrants to purchase 850,000 shares of Holdco common stock at an exercise price of $83.73 per share which become exercisable upon
achieving $75 million in net sales (trailing 12 months) of Valtech products; and (f) the right to receive a payment of $375 million (payable in cash or Holdco common stock, at the discretion of Holdco) upon achieving $450 million in net sales
(trailing 12 months) of Valtech products. The number of shares of Holdco common stock that Valtech shareholders will be entitled to receive will not be adjusted in the event of any increase or decrease in the share price of HeartWare common stock.
Each share of Holdco common stock will be issued in accordance with, and subject to the rights and obligations of, the Holdco Certificate
of Incorporation and Bylaws substantially in the forms attached hereto as Annex B. For a comparison of the rights and privileges of a holder of shares of Holdco common stock as compared to a holder of Valtech shares, please see Comparison
of the Rights of Holders of Valtech Shares and Holdco Common Stock beginning on page 146 of this proxy statement/prospectus.
The market value of the shares of Holdco common stock that Valtech shareholders and HeartWare stockholders will be entitled to receive at
Closing could vary significantly from the market value of HeartWare common stock on the date of this proxy statement/prospectus. Because the number of shares of Holdco common stock issued to the Recipient Parties will not be adjusted to reflect any
changes in the market value of HeartWare common stock, such market price fluctuations may affect the value that Valtech shareholders will receive at Closing. Share price changes may result from a variety of factors, including changes in the
business, operations or prospects of HeartWare or Valtech, market assessments of the likelihood that the Transactions will be completed, the timing of the Transactions, regulatory considerations, general market and economic conditions and other
factors. Shareholders are urged to obtain current market quotations for HeartWare common stock. See Comparative Per Share Data beginning on page 132 for additional information on the market value of HeartWare common stock.